Study guide / Liver changes and limits
What did tesamorelin liver fat studies find?
Small studies in people with HIV measured less liver fat. They didn't prove better liver health years later.
What is the short answer on tesamorelin liver fat?
The key liver trial was small; it was a 12-month study. Everyone had fatty liver and HIV.
Fatty liver is a buildup of fat when alcohol isn't the cause. These studies called a level under 5% normal.
Tesamorelin cut liver fat by about a third. Also, 35% of people fell below the 5% line.
Only 4% did so with placebo. Liver samples showed cells turned up fat-burning genes and turned down swelling genes.
These findings don't cover fatty liver in everyone. Tesamorelin isn't approved as a liver treatment.
How much liver fat changed in each trial?
Every study here was limited to people with HIV. None tested common fatty liver in everyone else.
The main 12-month trial included only 61 people. It compared tesamorelin 2 mg/day with placebo.
Liver fat was 37% lower with tesamorelin [6]. An MRI, which makes pictures inside the body, measured it.
Also, 35% reached liver fat below 5%. Only 4% on placebo got there [6].
The authors still called for longer liver study. Less fat doesn't prove less scarring years later.
An earlier 6-month trial followed 50 adults taking HIV drugs. Liver fat fell 2.9% more, while one belly-scan area fell 42 square centimeters more [3].
A 2026 review joined five trials. It reported a liver-fat drop and no serious harmful events [12].
A 2024 trial reported another drop with tesamorelin. Placebo showed a smaller drop instead [10].
That newer work stayed within HIV care. The tesamorelin liver fat results don't promise the same change for everyone.
What did tesamorelin studies find in liver samples?
Doctors examined small liver samples after 12 months. They checked which genes, the cells' written plans, were active.
Cells turned up genes that help burn fat [8]. They turned down genes tied to swelling and scars.
This came from liver tissue, not just a blood test. Even so, it didn't prove better health years later.
The gene changes may explain the fat drop. They don't show that tesamorelin cures liver disease.
Could tesamorelin treat fatty liver without HIV?
The 12-month trial had only 61 people, all with HIV. Tesamorelin 2 mg/day cut liver fat 37% more than placebo.
Also, 35% fell below 5% liver fat, versus 4% on placebo [6]. The authors called for more study, and broad liver use isn't approved.
Did more than one tesamorelin study find less liver fat?
A 6-month trial of 50 adults found 2.9% less liver fat [3]. Five trials later entered a 2026 review.
That review confirmed the liver-fat drop [12]. Every study involved HIV, not common fatty liver in everyone else.
How were IGF-1 and liver blood tests linked?
One added study examined 61 people with fatty liver and HIV. It compared liver fat, blood sugar, and IGF-1.
The liver makes this growth protein. People making less IGF-1 had more liver fat and worse blood sugar.
Carrier 1 and carrier 3 rose; carrier 2 and carrier 6 fell [13]. These are protein names, not amounts, and they carry IGF-1 through blood.
Another study began with high liver blood-test results. Those tests can rise when liver cells are strained.
People losing more belly fat had larger drops in those tests. Researchers checked the change over 26 weeks [14].
Blood-test results got better alongside the belly-fat loss. That doesn't prove tesamorelin helped liver cells on its own.
The research page explains the growth protein and hormone steps. The liver fat research page keeps this finding within HIV care.
What do tesamorelin liver studies still not show?
All liver results here came from HIV care. The 37% change [6] didn't come from the public at large.
Neither did the 2.9% result [3]. The review's finding also stayed within HIV studies [12].
People taking HIV drugs supplied the 2024 result too [10]. Broad proof for those without HIV is still missing.
A second gap concerns lasting liver harm. An MRI can measure fat but can't settle future scarring.
The authors said liver tissue needs longer follow-up [6]. Less measured fat isn't the same as fewer liver problems years later.
Tesamorelin is approved only for the belly-fat illness tied to HIV [5]. Liver care with the drug remains unapproved and unproved.